A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05734066` - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma	Phase 1/Phase 2
Completed	`NCT02546544` - Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma	Phase 2
Completed	`NCT04661852` - Cabozantinib With Topotecan-Cyclophosphamide	Phase 1
Active, not recruiting	`NCT03635632` - C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)	Phase 1

See also

Status

Clinical Trial

Phase

Recruiting

NCT05734066 - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Phase 1/Phase 2

Completed

NCT02546544 - Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Phase 2

Completed

NCT04661852 - Cabozantinib With Topotecan-Cyclophosphamide

Phase 1

Active, not recruiting

NCT03635632 - C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03514407
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 1
Start date	June 27, 2018
Completion date	June 25, 2020

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms